# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-24-022446
Filing Date
2024-04-26
Accepted
2024-04-26 16:10:50
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | ny20022201x2_defa14a.htm | DEFA14A | 8736
2 |  | ny20022201x2_nc03.jpg | GRAPHIC | 943478
3 |  | ny20022201x2_nc04.jpg | GRAPHIC | 616770
| Complete submission text file | 0001140361-24-022446.txt |  | 2085484

Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-24006 | Film No.: 24883777
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)